Synthesis of a novel series of tetracyclic opioid antagonists incorporating an 8-aminobicyclo[3.2.1]oct-6-ene sub-unit

Tetrahedron Letters

Volumn 44, Issue 46, 2003, Pages 8411-8415

  Miller, J A ^a,b   Pope, S A ^a   Riddall, D R ^a   Ullah, G M ^a   Welsh, G M ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^b Tularik Ltd   (United Kingdom)

Author keywords

Alkynes; Allyl cations; Bicycle 3.2.1 oct ene ane amines; Dezocine; Opioid antagonist; 3+2 cycloaddition; receptors

Indexed keywords

8 AMINOBICYCLO[3.2.1]OCT 6 ENE; ALCOHOL DERIVATIVE; ALKENE DERIVATIVE; ALKYNE; AMINE; MU OPIATE RECEPTOR; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CYCLOADDITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS;

EID: 0141956510     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2003.09.104     Document Type: Article

References (35)

1. Miller J.A., Moore M. Tetrahedron Lett. 21:1980;577-580.
2. Gray B.D., McMillan C.M., Miller J.A., Moore M. Tetrahedron Lett. 28:1987;235-238.
3. Gray B.D., McMillan C.M., Miller J.A., Ullah G.M. Tetrahedron Lett. 28:1987;689-692.
4. Miller J.A., Ullah G.M., Welsh G.M., Mallon P. Tetrahedron Lett. 42:2001;2729-2731.
5. Miller J.A., Ullah G.M., Welsh G.M., Hall A.C. Tetrahedron Lett. 42:2001;7503-7507.
6. Thorpe D.H. Anasth. Analg. 63:1984;143-151.
7. Beckett A.H., Casey A.F. J. Pharm. Pharmacol. 6:1954;986-1001.
8. Portoghese P.S. J. Med. Chem. 8:1965;609-616.
9. Snyder S.H., Pasternak G.W. Trends Pharmacol. Sci. 24:2003;198-205.
10. Hanessian S., Parthsarathy S., Mauduit M., Payza K. J. Med. Chem. 46:2003;34-48.
11. Freed M.E., Potoski J.R., Freed E.H., Conklin G.L. J. Med. Chem. 16:1973;595-599.
12. Freed M.E., Potoski J.R., Freed E.H., Conklin G.L., Bell S.C. J. Med. Chem. 19:1976;476-480.
13. Freed M.E., Potoski J.R., Conklin G.L., Bell S.C. J. Med. Chem. 19:1976;560-562.
14. Malis J.L., Rosenthale M.E., Gluckman M.I. J. Pharm. Exper. Ther. 194:1975;488-498 Acute Pain; Smith, G.; Covino, B. G., Eds.; Butterworths: London, 1985; pp. 92-93.
15. Malis J.L., Rosenthale M.E., Gluckman M.I. J. Pharm. Exper. Ther. 194:1975;488-498 Acute Pain; Smith, G.; Covino, B. G., Eds.; Butterworths: London, 1985; pp. 92-93.
16. Sisenwine S.F., Tio C.O. Drug Metab. Dispos. 9:1981;37.
17. Oosterlinck W., Verbaeys A. Curr. Med. Res. Opin. 6:1980;472 Downing, J. W.; Brock-Utne. J. G.; Barclay, A.; Schwegmann, I. L. Brit. J. Anaesth. 1981, 53, 59; SCRIP 1991, 1625, 20.
18. Oosterlinck W., Verbaeys A. Curr. Med. Res. Opin. 6:1980;472 Downing, J. W.; Brock-Utne. J. G.; Barclay, A.; Schwegmann, I. L. Brit. J. Anaesth. 1981, 53, 59; SCRIP 1991, 1625, 20.
19. Oosterlinck W., Verbaeys A. Curr. Med. Res. Opin. 6:1980;472 Downing, J. W.; Brock-Utne. J. G.; Barclay, A.; Schwegmann, I. L. Brit. J. Anaesth. 1981, 53, 59; SCRIP 1991, 1625, 20.
20. Pope, S. A., Internal Report, Wellcome Foundation Ltd., 1985.
21. Basic Pharmacology, 4th ed.; Foster, R. W., Ed.; Butterworth-Heinemann: Oxford, 1996; p. 243 Gutstein, H. B.; Akil, H. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; Hardman, J. G.; Limbard, L. E., Eds.; McGraw-Hill: New York, 2001; Chapter 23, pp. 569-578.
22. Pan Z.Z., Tershner S.A., Fields H.L. Nature. 389:1997;382-385.
23. Julius D. Nature. 386:1997;442.
24. Stork G., Brizzolara H., Landesman H., Szmuszkovicz J., Terrell R. J. Am. Chem. Soc. 85:1963;207-222.
25. Ziegler F.E., Hwang K.-J. J. Org. Chem. 48:1983;3349-3351.
26. Piers E., Britton B.W., Geraghty M.B., Keziere R.J., Kido F. Can. J. Chem. 53:1975;2838-2848.
27. Piers E., Geraghty M.B., Keziere R.J., Smillie R.D., Soucy M. Can. J. Chem. 53:1975;2849-2864.
28. Gray B.D., Miller J.A. J. Chem. Res. (S). 1987;206-207 Gray B. D., PhD Thesis, University of Dundee, 1983 McMillan C. M., PhD Thesis, University of Dundee, 1984.
29. Gray B.D., Miller J.A. J. Chem. Res. (S). 1987;206-207 Gray B. D., PhD Thesis, University of Dundee, 1983 McMillan C. M., PhD Thesis, University of Dundee, 1984.
30. Gray B.D., Miller J.A. J. Chem. Res. (S). 1987;206-207 Gray B. D., PhD Thesis, University of Dundee, 1983 McMillan C. M., PhD Thesis, University of Dundee, 1984.
31. 2 and the quaternary Me group - the latter showed a strong NOE and a deshielded shift at 1.4 ppm. Other confirmatory evidence came from an earlier X-ray structure determination, see: Gray, B. D.; Miller, J. A.; Weakley T. J. R. Acta. Crystallogr. 1987, C43, 2427-2429.
32. Appropriate analytical and spectral data (NMR and ms) have been obtained on compounds subject to bioassay.
33. Pert C.B., Snyder S.H. Mol. Pharmacol. 10:1974;868-879.
34. Bishop M.J., Garrido D.M., Boswell G.E., Collins M.A., Harris P.A., McNutt R.W., O'Neill S.J., Wei K., Chang K.-J. J. Med. Chem. 46:2003;623-633.
35. Williams M., Kowaluk E.A., Arneric S.P. J. Med. Chem. 42:1999;1481-1500.